Expression of novel markers of pancreatic ductal adenocarcinoma in pancreatic nonductal neoplasms: Additional evidence of different genetic pathways

Modern Pathology

Volumn 18, Issue 6, 2005, Pages 752-761

  Cao, Dengfeng ^a   Maitra, Anirban ^a   Saavedra, Jorge Albores ^b   Klimstra, David S ^c   Adsay, N Volkan ^d   Hruban, Ralph H ^a,e  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b Louisiana State University School of Medicine Shreveport   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d WAYNE STATE UNIVERSITY   (United States)

^e JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

Acinar cell carcinoma; Novel markers; Pancreatic ductal adenocarcinoma; Pancreatoblastoma; Solid pseudopapillary tumor; Tissue microarray; Undifferentiated carcinoma with osteoclastic like giant cells

Indexed keywords

BETA CATENIN; CYTOKERATIN 19; DNA TOPOISOMERASE (ATP HYDROLYSING); FASCIN; FIBRONECTIN; GAMMA SYNUCLEIN; HEAT SHOCK PROTEIN 47; MESOTHELIN; PROSTATE STEM CELL ANTIGEN; PROTEIN 14 3 3; SMAD4 PROTEIN; TUMOR MARKER; UNCLASSIFIED DRUG;

ACINAR CELL CARCINOMA; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; EPITHELIUM CELL; GENE EXPRESSION; GENETICS; GIANT CELL; HUMAN; HUMAN TISSUE; ONCOGENE; OSTEOCLAST; PANCREAS ADENOCARCINOMA; PANCREAS SOLID PSEUDOPAPILLARY TUMOR; PANCREAS TUMOR; PANCREATOBLASTOMA; PATHOGENESIS; PRIORITY JOURNAL; STROMA CELL; TISSUE MICROARRAY; TUMOR SUPPRESSOR GENE; UNDIFFERENTIATED CARCINOMA;

BETA CATENIN; CARCINOMA, ACINAR CELL; CARCINOMA, PANCREATIC DUCTAL; CARRIER PROTEINS; CYTOSKELETAL PROTEINS; DNA-BINDING PROTEINS; EXONUCLEASES; FIBRONECTINS; GAMMA-SYNUCLEIN; HEAT-SHOCK PROTEINS; HSP47 HEAT-SHOCK PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; KERATINS; MEMBRANE GLYCOPROTEINS; MICROFILAMENT PROTEINS; NEOPLASM PROTEINS; NERVE TISSUE PROTEINS; PANCREATIC NEOPLASMS; SERPINS; SMAD4 PROTEIN; SYNUCLEINS; TRANS-ACTIVATORS; TUMOR MARKERS, BIOLOGICAL;

EID: 20344379938     PISSN: 08933952     EISSN: None     Source Type: Journal    
DOI: 10.1038/modpathol.3800363     Document Type: Article

References (77)

1. De Jong SA, Pickleman J, Rainsford K. Nonductal tumors of the pancreas. The importance of laparotomy. Arch Surg 1993;128:730-734.
2. Sheehan M, Latona C, Aranha G, et al. The increasing problem of unusual pancreatic tumors. Arch Surg 2000;135:644-648.
3. Kosmahl M, Pauser U, Peters K, et al. Cystic neoplasms of the pancreas and tumor-like lesions with cystic features: a review of 418 cases and a classification proposal. Virchows Arch 2004;445:168-178.
4. Klimstra DS, Wenig BM, Adair CF, et al. Pancreatoblastoma. A clinicopathologic study and review of the literature. Am J Surg Pathol 1995;19:1371-1389.
5. Shorter NA, Glick RD, Klimstra DS, et al. Malignant pancreatic tumors in childhood and adolescence: the Memorial Sloan-Kettering experience, 1967 to present. J Pediatr Surg 2002;37:887-892.
6. Klimstra DS, Heffess CS, Oertel JE, et al. Acinar cell carcinoma of the pancreas. A clinicopathologic study of 28 cases. Am J Surg Pathol 1992;16:815-837.
7. Ordonez NG. Pancreatic acinar cell carcinoma. Adv Anat Pathol 2001;8:144-159.
8. Molberg KH, Heffess C, Delgado R, et al. Undifferentiated carcinoma with osteoclast-like giant cells of the pancreas and periampullary region. Cancer 1998;82:1279-1287.
9. Hoorens A, Prenzel K, Lemoine NR, et al. Undifferentiated carcinoma of the pancreas: analysis of intermediate filament profile and Ki-ras mutations provides evidence of a ductal origin. J Pathol 1998;185:53-60.
10. Swierczynski SL, Maitra A, Abraham SC, et al. Analysis of novel tumor markers in pancreatic and biliary carcinomas using tissue microarrays. Hum Pathol 2004;35:357-366.
11. Maitra A, Adsay NV, Argani P, et al. Multicomponent analysis of the pancreatic adenocarcinoma progression model using a pancreatic intraepithelial neoplasia tissue microarray. Mod Pathol 2003;16:902-912.
12. Iacobuzio-Donahue CA, Maitra A, Olsen M, et al. Exploration of global gene expression patterns in pancreatic adenocarcinoma using cDNA microarrays. Am J Pathol 2003;162:1151-1162.
13. Iacobuzio-Donahue CA, Maitra A, Shen-Ong GL, et al. Discovery of novel tumor markers of pancreatic cancer using global gene expression technology. Am J Pathol 2002;160:1239-1249.
14. Argani P, Rosty C, Reiter RE, et al. Discovery of new markers of cancer through serial analysis of gene expression: prostate stem cell antigen is overexpressed in pancreatic adenocarcinoma. Cancer Res 2001;61:4320-4324.
15. Argani P, Iacobuzio-Donahue C, Ryu B, et al. Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin Cancer Res 2001;7: 3862-3868.
16. Osborn M, van Lessen G, Weber K, et al. Differential diagnosis of gastrointestinal carcinomas by using monoclonal antibodies specific for individual keratin polypeptides. Lab Invest 1986;55:497-504.
17. Maitra A, Iacobuzio-Donahue C, Rahman A, et al. Immunohistochemical validation of a novel epithelial and a novel stromal marker of pancreatic ductal adenocarcinoma identified by global expression microarrays: sea urchin fascin homolog and heat shock protein 47. Am J Clin Pathol 2002;118:52-59.
18. Hahn SA, Schutte M, Hoque AT, et al. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 1996;271:350-353.
19. Lagna G, Hata A, Hemmati-Brivanlou A, et al. Partnership between DPC4 and SMAD proteins in TGF-beta signalling pathways. Nature 1996;383:832-836.
20. Schutte M, Hruban RH, Hedrick L, et al. DPC4 gene in various tumor types. Cancer Res 1996;56:2527-2530.
21. Abraham SC, Klimstra DS, Wilentz RE, et al. Solid-pseudopapillary tumors of the pancreas are genetically distinct from pancreatic ductal adenocarcinomas and almost always harbor beta-catenin mutations. Am J Pathol 2002;160:1361-1369.
22. Abraham SC, Klimstra DS, Wilentz RE, et al. Distinctive molecular genetic alterations in sporadic and familial adenomatous polyposis-associated pancreatoblastomas: frequent alterations in the APC/beta-catenin pathway and chromosome lip. Am J Pathol 2001;159:1619-1627.
23. Imai Y, Morishita S, Ikeda Y, et al. Immunohistochemical and molecular analysis of giant cell carcinoma of the pancreas: a report of three cases. Pancreas 1999; 18:308-315.
24. Abraham SC, Wu TT, Hruban RH, et al. Genetic and immunohistochemical analysis of pancreatic acinar cell carcinoma: frequent allelic loss on chromosome lip and alterations in the APC/beta-catenin pathway. Am J Pathol 2002;160:953-962.
25. Hermeking H, Lengauer C, Polyak K, et al. 14-3-3 sigma is a p53-regulated inhibitor of G2/M progression. Mol Cell 1997;1:3-11.
26. Hermeking H. The 14-3-3 cancer connection. Nat Rev Cancer 2003;3:931-943.
27. Ferguson AT, Evron E, Umbricht CB, et al. High frequency of hypermethylation at the 14-3-3 sigma locus leads to gene silencing in breast cancer. Proc Natl Acad Sci USA 2000;97:6049-6054.
28. Moreira JM, Gromov P, Celis JE. Expression of the tumor suppressor protein 14-3-3 sigma is down regulated in invasive transitional cell carcinomas of the urinary bladder undergoing epithelial-to-mesenchymal transition. Mol Cell Proteomics 2004;3:410-419.
29. Gasco M, Bell AK, Heath V, et al. Epigenetic inactivation of 14-3-3 sigma in oral carcinoma: association with p16 (INK4a) silencing and human papillomavirus negativity. Cancer Res 2002;62:2072-2076.
30. Gasco M, Sullivan A, Repellin C, et al. Coincident inactivation of 14-3-3sigma and p16INK4a is an early event in vulval squamous neoplasia. Oncogene 2002; 21:1876-1881.
31. Iwata N, Yamamoto H, Sasaki S, et al. Frequent hypermethylation of CpG islands and loss of expression of the 14-3-3 sigma gene in human hepatocellular carcinoma. Oncogene 2000;19:5298-5302.
32. Osada H, Tatematsu Y, Yatabe Y, et al. Frequent and histological type-specific inactivation of 14-3-3sigma in human lung cancers. Oncogene 2002;21: 2418-2424.
33. Lodygin D, Yazdi AS, Sander CA, et al. Analysis of 14-3-3sigma expression in hyperproliferative skin diseases reveals selective loss associated with CpG-methylation in basal cell carcinoma. Oncogene 2003; 22:5519-5524.
34. Nelson WJ, Nusse R. Convergence of Wnt, beta-catenin, and cadherin pathways. Science 2004;303: 1483-1487.
35. Aberle H, Bauer A, Stappert J, et al. Beta-catenin is a target for the ubiquitin-proteasome pathway. EMBO J 1997;16:3797-3804.
36. Orford K, Crockett C, Jensen JP, et al. Serine phosphorylation-regulated ubiquitination and degradation of beta-catenin. J Biol Chem 1997;272:24735- 24738.
37. Morin PJ, Sparks AB, Korinek V, et al. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 1997;275: 1787-1790.
38. Korinek V, Barker N, Morin PJ, et al. Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/- colon carcinoma. Science 1997;275: 1784-1787.
39. Tanaka Y, Kato K, Notohara K, et al. Significance of aberrant (cytoplasmic/nuclear) expression of beta-catenin in pancreatoblastoma. J Pathol 2003;199:185-190.
40. Isaacs RJ, Davies SL, Sandri MI, et al. Physiological regulation of eukaryotic topoisomerase II. Biochim Biophys Acta 1998;1400:121-137.
41. Meyer KN, Kjeldsen E, Straub T, et al. Cell cycle-coupled relocation of types I and II topoisomerases and modulation of catalytic enzyme activities. J Cell Biol 1997;136:775-788.
42. Tran CP, Lin C, Yamashiro J, et al. Prostate stem cell antigen is a marker of late intermediate prostate epithelial cells. Mol Cancer Res 2002;1:113-121.
43. Reiter RE, Gu Z, Watabe T, et al. Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer. Proc Natl Acad Sci USA 1998;95: 1735-1740.
44. Amara N, Palapattu GS, Schrage M, et al. Prostate stem cell antigen is overexpressed in human transitional cell carcinoma. Cancer Res 2001;61:4660-4665.
45. Cao D, Ji H, Ronnett BM. Expression of mesothelin, fascin, and prostate stem cell antigen in primary ovarian mucinous tumors and their utility in differentiating primary ovarian mucinous tumors from metastatic pancreatic mucinous carcinomas in the ovary. Int J Gynecol Pathol, in press.
46. Dannull J, Diener PA, Prikler L, et al. Prostate stem cell antigen is a promising candidate for immunotherapy of advanced prostate cancer. Cancer Res 2000;60: 5522-5528.
47. Hassan R, Viner JL, Wang QC, et al. Anti-tumor activity of K1-LysPE38QQR, an immunotoxin targeting mesothelin, a cell-surface antigen overexpressed in ovarian cancer and malignant mesothelioma. J Immunother 2000;23:473-479.
48. Ordonez NG. The immunohistochemical diagnosis of mesothelioma: a comparative study of epithelioid mesothelioma and lung adenocarcinoma. Am J Surg Pathol 2003;27:1031-1051.
49. Chang K, Pastan I. Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci USA 1996;93:136-140.
50. Frierson Jr HF, Moskaluk CA, Powell SM, et al. Large-scale molecular and tissue microarray analysis of mesothelin expression in common human carcinomas. Hum Pathol 2003;34:605-609.
51. Kasper M, von Dorsche H, Stosiek P. Changes in the distribution of intermediate filament proteins and collagen IV in fetal and adult human pancreas. I. Localization of cytokeratin polypeptides. Histochemistry 1991;96:271-277.
52. Real FX, Vila MR, Skoudy A, et al. Intermediate filaments as differentiation markers of exocrine pancreas. II. Expression of cytokeratins of complex and stratified epithelia in normal pancreas and in pancreas cancer. Int J Cancer 1993;54:720-727.
53. Notohara K, Hamazaki S, Tsukayama C, et al. Solid-pseudopapillary tumor of the pancreas: immunohistochemical localization of neuroendocrine markers and CD10. Am J Surg Pathol 2000;24:1361-1371.
54. Kureishy N, Sapountzi V, Prag S, et al. Fascins and their roles in cell structure and function. Bioessays 2002;24:350-361.
55. Tao YS, Edwards RA, Tubb B, et al. beta-Catenin associates with the actin-bundling protein fascin in a noncadherin complex. J Cell Biol 1996;134:1271-1281.
56. Gerdes B, Ramaswamy A, Simon B, et al. Analysis of beta-catenin gene mutations in pancreatic tumors. Digestion 1999;60:544-548.
57. Grothey A, Hashizume R, Ji H, et al. C-erbB-2/HER-2 upregulates fascin, an actin-bundling protein associated with cell motility, in human breast cancer cell lines. Oncogene 2000;19:4864-4875.
58. Nagata K. HSP47 as a collagen-specific molecular chaperone: function and expression in normal mouse development. Semin Cell Dev Biol 2003;14:275-282.
59. Hebert C, Norris K, Della Coletta R, et al. Cell surface colligin/Hsp47 associates with tetraspanin protein CD9 in epidermoid carcinoma cell lines. J Cell Biochem 1999;73:248-258.
60. Ollins GJ, Nikitakis N, Norris K, et al. The production of the endostatin precursor collagen XVIII in head and neck carcinomas is modulated by CBP2/Hsp47. Anticancer Res 2002;22:1977-1982.
61. Shirakami T, Tsuzuki T, Iijima H, et al. Inhibition of HSP47 during the transition from solid to ascitic form of Sarcoma 180 in vivo. In Vivo 1995;9:509-512.
62. Morino M, Tsuzuki T, Iijima H, et al. Marked induction of HSP47, a collagen-binding stress protein, during solid tumor formation of ascitic sarcoma 180 in vivo. In Vivo 1995;9:503-508.
63. Franke FE, Von Georgi R, Zygmunt M, et al. Association between fibronectin expression and prognosis in ovarian carcinoma. Anticancer Res 2003;23:4261-4267.
64. Birchler MT, Milisavlijevic D, Pfaltz M, et al. Expression of the extra domain B of fibronectin, a marker of angiogenesis, in head and neck tumors. Laryngoscope 2003;113:1231-1237.
65. Han JY, Kim HS, Lee SH, et al. Immunohistochemical expression of integrins and extracellular matrix proteins in non-small cell lung cancer: correlation with lymph node metastasis. Lung Cancer 2003;41:65-70.
66. Vialle-Castellano A, Gaugler B, Mohty M, et al. Abundant expression of fibronectin is a major feature of leukemic dendritic cells differentiated from patients with acute myeloid leukemia. Leukemia 2004;18: 426-433.
67. Miyamoto H, Murakami T, Tsuchida K, et al. Tumor-stroma interaction of human pancreatic cancer: acquired resistance to anticancer drugs and proliferation regulation is dependent on extracellular matrix proteins. Pancreas 2004;28:38-44.
68. Vaquero EC, Edderkaoui M, Nam KJ, et al. Extracellular matrix proteins protect pancreatic cancer cells from death via mitochondrial and nonmitochondrial pathways. Gastroenterology 2003;125:1188-1202.
69. Kijima T, Maulik G, Ma PC, et al. Fibronectin enhances viability and alters cytoskeletal functions (with effects on the phosphatidylinositol 3-kinase pathway) in small cell lung cancer. J Cell Mol Med 2003;7:157-164.
70. Fornaro M, Plescia J, Chheang S, et al. Fibronectin protects prostate cancer cells from tumor necrosis factor-alpha-induced apoptosis via the AKT/survivin pathway. J Biol Chem 2003;278:50402-50411.
71. Clayton DF, George JM. The synucleins: a family of proteins involved in synaptic function, plasticity, neurodegeneration and disease. Trends Neurosci 1998;21:249-254.
72. George JM. The synucleins. Genome Biol 2002;3: REVIEWS3002.
73. Ji H, Liu YE, Jia T, et al. Identification of a breast cancer-specific gene, BCSG1, by direct differential cDNA sequencing. Cancer Res 1997;57:759-764.
74. Bruening W, Giasson BI, Klein-Szanto AJ, et al. Synucleins are expressed in the majority of breast and ovarian carcinomas and in preneoplastic lesions of the ovary. Cancer 2000;88:2154-2163.
75. Wu K, Weng Z, Tao Q, et al. Stage-specific expression of breast cancer-specific gene gamma-synuclein. Cancer Epidemiol Biomarkers Prev 2003;12:920-925.
76. Gupta A, Godwin AK, Vanderveer L, et al. Hypomethylation of the synuclein gamma gene CpG island promotes its aberrant expression in breast carcinoma and ovarian carcinoma. Cancer Res 2003;63:664-673.
77. Pan ZZ, Bruening W, Giasson BI, et al. Gamma-synuclein promotes cancer cell survival and inhibits stress- and chemotherapy drug-induced apoptosis by modulating MAPK pathways. J Biol Chem 2002;277: 35050-35060.